FemRx' Opera Star cleared for US marketing
This article was originally published in Clinica
Gynaecology specialist FemRx has received 510(k) clearance for its minimally invasive alternative to hysterectomy, the Opera Star system. The Out-Patient Endometrial Resection/Ablation device treats abnormal uterine bleeding in most patients without the need for an incision (see Clinica No 696, p 10). The system consists of a Specialised Tissue Aspirating Resectoscope which enables gynaecological surgeons to resect and ablate the endometrial lining and remove fibroids while continuously aspirating tissue for pathological evaluation.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.